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Abstract: Melanoma of the skin has become a prime example for demonstrating the success of targeted
cancer therapy. Nevertheless, high mortality has remained, mainly related to tumor heterogeneity and
inducible therapy resistance. But the development of new therapeutic strategies and combinations
has raised hope of finally defeating this deadly disease. TNF-related apoptosis-inducing ligand
(TRAIL) represents a promising antitumor strategy. The principal sensitivity of melanoma cells for
TRAIL was demonstrated in previous studies; however, inducible resistance appeared as a major
problem. To address this issue, combination strategies were tested, and survival pathway inhibitors
were shown to sensitize melanoma cells for TRAIL-induced apoptosis. Finally, cell cycle inhibition
was identified as a common principle of TRAIL sensitization in melanoma cells. Mitochondrial
apoptosis pathways, pro- and antiapoptotic Bcl-2 proteins as well as the rheostat consisted of Smac
(Second mitochondria-derived activator of caspase) and XIAP (X-linked inhibitor of apoptosis protein)
appeared to be of particular importance. Furthermore, the role of reactive oxygen species (ROS) was
recognized in this setting. Inducible TRAIL resistance in melanoma can be explained by (i) high levels
of antiapoptotic Bcl-2 proteins, (ii) high levels of XIAP, and (iii) suppressed Bax activity. These hurdles
have to be overcome to enable the use of TRAIL in melanoma therapy. Several strategies appear as
particularly promising, including new TRAIL receptor agonists, Smac and BH3 mimetics, as well as
selective kinase inhibitors.
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1. Still High Mortality of Melanoma Despite Efficient New Therapies (Introduction)
While the incidence of most solid tumors has decreased or at least stabilized in the last decades,
the incidence of skin cancer has continued to rise worldwide [1]. It is particularly a problem of
the Caucasian populations with light skin and too much UV radiation. Skin cancer is subdivided
into melanoma and non-melanoma skin cancer, the latter mainly enclosing basal cell carcinoma and
cutaneous squamous cell carcinoma. Other non-melanoma skin cancers such as Merkel cell carcinoma
and cutaneous T-cell lymphoma are less frequent. In the United States, non-melanoma skin cancer
is the most common and melanoma the sixth most common cancer [2]. The situation appears as
comparable in Europe and even worse in Australia [3,4].
With regard to melanoma, the problems of early dissemination and pronounced chemotherapy
resistance remained completely unsolved for decades [5]. Just in recent years, the situation significantly
improved due to (i) the development of targeted therapy based on selective inhibitors for the MAP
kinases BRAF (B-Raf proto-oncogene) and MEK (MAPK/ERK kinase) and (ii) due to the development of
efficient immune-stimulating antibodies such anti-CTLA4 (cytotoxic T-lymphocyte-associated protein),
anti-PD1 (programmed cell death), and anti-PDL1 (PD1 ligand). Together, these new strategies now
enable a significant prolongation of overall survival of metastatic melanoma patients [6,7]. Nevertheless,
for many patients, tumor relapse and therapy resistance often follow within only a few months or years,
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after a phase of initial tumor reduction [2,8]. Thus, new combination partners are still needed, which
may further improve the clinical outcome. Many drug candidates have been investigated, and TRAIL
(Tumor Necrosis Factor α-related apoptosis-inducing ligand) appears as promising.
2. Apoptosis Deficiency Is a Major Cause of Melanoma Therapy Resistance
A number of cellular mechanisms contribute to the development of cancer, which have been listed
in the often-cited hallmarks of cancer [9]. Concerning therapy resistance, apoptosis deficiency may
have the most decisive contribution. This is suggested by the principal need to finally eliminate the
tumor cells, and apoptosis induction appears as the most common and most efficient way of doing so.
Apoptosis is also the end path of many anticancer therapies in melanoma. Thus, chemotherapeutic
drugs cause DNA defects or other kinds of cellular damage, which activate intrinsic, proapoptotic
pathways in melanoma cells [10]. Also, BRAF inhibition in melanoma cells has been related to an
induction of apoptosis as well as to a sensitization for other proapoptotic effectors. Thus, TRAIL-induced
apoptosis was strongly enhanced, and TRAIL resistance was overcome in melanoma cells by BRAF
inhibitors, including vemurafenib approved for melanoma therapy [11–13]. Finally, the stimulation of
an anti-tumor immune response results in activation of cytotoxic T-lymphocytes, which also express
death ligands to trigger extrinsic proapoptotic pathways in target cancer cells [14]. Therapeutic
strategies that aim at the reinforcement of apoptosis pathways thus appear as important. Furthermore,
sensitization of melanoma cells for TRAIL-induced apoptosis may support an anti-tumor immune
response, also based on the expression of death ligands. In the light of the breakthrough of approved
immune-stimulating therapies in melanoma, this issue gets a particular meaning [6,7].
3. Induction of Apoptosis by Death Ligands
Extrinsic proapoptotic pathways are triggered by death ligands such as TNF-α, CD95L/FasL, or TRAIL,
which bind to cognate death receptors (TNF-R1, CD95/Fas, TRAIL-R1/DR4, and TRAIL-R2/DR5, Figure 1).
Melanoma cells reveal principal sensitivity to CD95L as well as to TRAIL [15,16]. Death receptors
can activate proapoptotic initiator caspases as well as the NF-κB pathway with mainly antiapoptotic
functions [17]. In contrast, TNF-R2 is not linked to caspase activation, and decoy receptors work
antagonistically, as they can bind death ligands but do not transduce the signal [18]. For TRAIL sensitivity
of melanoma cells, decoy receptors (DcR1 and DcR2) may play a minor role, as only week expression
was found in melanoma cell lines [19]. Ligand binding to death receptors leads to the formation of a
death-inducing signaling protein complex (DISC, Figure 2), where initiator caspases-8 and -10 are activated
by induced proximity and autocatalytic proteolysis [20,21]. Initiator caspases can drive the processing
and activation of effector caspases-3, -6 and -7, which cleave a large number of so-called death substrates
to irreversibly set apoptosis into work [22].
The extrinsic apoptosis pathway is negatively regulated by antagonistic proteins. Thus, c-FLIP
(cellular FLICE-inhibitory protein) serves as a competitive inhibitor of caspase-8/-10; it can bind to
the DISC but does not promote effector caspase activation [23,24]. Further downstream, the family of
cellular inhibitor of apoptosis proteins (cIAPs) can bind to effector caspases and thus prevent their
proteolytic activity [25,26] (Figure 2). Significant roles of both c-FLIP and XIAP (chromosome X-linked
IAP) have been shown for TRAIL resistance of melanoma cells [27,28].
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Figure 1. Death receptors activate proapoptotic caspase cascades as well as NF-κB.  Figure 1. Death receptors activate proapoptotic caspase cascades as well as NF-κB. Binding of
death ligands (TNF-α, CD95L/FasL, and TRAIL) to cognate receptors is shown. These share up
to four cysteine-rich extracellular domains (grey hexagons). Death receptors (TNF-R1, CD95/Fas,
TRAIL-R1/DR4, and TRAIL-R2/DR5) are further characterized by an intracellular death domain (red
box), which allows binding of the adaptor protein FADD (Fas-associated death domain). TNF-R1
binds adaptor protein TRADD (TNF receptor-associated death domain), which further mediates
FADD binding, while the intracellular domain of TNF-R2 (blue box) binds to TRAF proteins (TNF
receptor-associated factors). Decoy receptors are characterized by lacking an intracellular domain
(DcR-1), by a non-functional intracellular domain (DcR-2, yellow box), or by lacking a functional
transmembrane domain (DcR-3, OPG, osteoprotegerin). FADD mediates proapoptotic caspase activation
via caspase-8 and/or caspase-10 (red arrowheads) and may also support NF-κB (nuclear factor kappaB)
activation, with mainly antiapoptotic functions (green arrowheads). In contrast, TNF-R2 via TRAF2/3
does not support caspase activation but activates NF-κB.
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Figure 2. Extrinsic proapoptotic signaling. Binding of death ligands (e.g., TRAIL) to cognate death
receptors (e.g., DR4, DR5) leads to the formation of a death-inducing signaling complex (DISC) within the
cytoplasma membran (CM), where initiator caspases-8 a -10 (Csp-8, Csp-10) bind vi the adaptor protein
FADD. Initiator caspases lead to the processing and activation of effector caspases (Csp-3, -6, -7), which
mediate the processing of death substrates (poin of no return). Csp-8, and -10 are n gatively controlled by
the competitive inhibitor, c-FLIP, while effector caspases are inhibited through binding of cellular inhibitor
of apoptosis proteins (cIAPs). Caspase-8 can also activate a mitochondrial amplification loop via cleavage
and activation of Bid to truncated Bid (tBid), a proapoptotic BH3-only protein. Arrowheads indicate
activation while blunt ends indicate inhibition; scissors (
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and Mcl-1 have been described [15,40,42].  
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with the different antiapoptotic Bcl-2 proteins in a competitive way to thus release Bax and Bak. BH3-
only proteins can be activated in the course of various cellular stress situations either by induced 
expression, or by translocation and/or protein modification, e.g., phosphorylation [37,43]. In this way, 
BH3-only proteins function as sensitizers for apoptosis induction through inhibition of antiapoptotic 
Bcl-2 proteins. In addition, some of them may also directly activate Bax, as reported for Bid, Bim, and 
Puma [44]. Furthermore, several subsequent steps are regulated by cellular kinases, such as by 
phosphorylation of antiapoptotic Bcl-2 proteins, by phosphorylation of Bax, or by affecting 
mitochondrial functions to release ROS [11,45,46] (Figure 3). Due to the important role of intrinsic 
apoptosis pathways in melanoma cells, Bcl-2 proteins appear as critical targets for melanoma therapy 
[15,47], and particularly efficient apoptosis induction was found for Bim and Puma [38,48,49]. 
5. Critical Role of Apoptosis Deficiency in Melanoma 
In normal tissue, homeostasis is maintained by a well-balanced equilibrium of cell proliferation 
and cell death [50]. Because of its critical meaning for the cell´s fate, apoptosis pathways are tightly 
regulated. Induction of apoptosis also serves as an important safeguard mechanism to prevent cancer 
by eliminating potentially harmful cells. A defective proapoptotic signaling thus represents a critical 
hallmark of cancer [9]. Apoptosis deficiency firstly permits initial tumor growth, and then it critically 
contributes to therapy resistance in advanced cancer. Apoptosis deficiency can be mediated by 
activation of antiapoptotic signals as well as by inactivation of proapoptotic pathways. Due to the 
important role of intrinsic, proapoptotic pathways in melanoma, pro- and antiapoptotic Bcl-2 
proteins come into particular focus [47,51]. 
The pronounced chemotherapy resistance of melanoma is highly suggestive for deficient 
apoptosis programs [36]. Survival pathways are frequently activated, as seen by the high frequency 
of mutations in N-RAS (Rat sarcoma oncogene; 10–25%) and in BRAF (40–60%) [52]. The pathways 
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4. Induction of Apoptosis by Intrinsic Signals
Intrinsic apoptosis pathways are initiated by different kinds of cellular dysregulation, e.g., by DNA
damage and/or chemotherapy (Figure 3). A central event here is the proapoptotic activation of
mitochondria, which encloses depolarization of the mitochondrial membrane potential (∆ψm) and the
release of proapoptotic mitochondrial factors, such as cytochrome c, second mitochondria-derived
activator of caspases (Smac), apoptosis-inducing factor, and endonuclease G [29,30]. Cytosolic
cytochrome c induces formation of the apoptosome, a multiprotein complex enclosing the adapter
protein Apaf-1, which leads to initiator caspase-9 activation. Furthermore, Smac contributes to
the activation of the caspase cascade, as it functions as an antagonist of cIAPs, e.g., of XIAP [31].
In contrast, apoptosis-inducing factor and endonuclease G contribute to apoptosis induction in
caspase-independent ways, namely by supporting DNA fragmentation in the nucleus [32,33].
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Figure 3. Intrinsic proapoptotic signali g. Death signals and survival signals affect the control
level of cellular kinases in opposite directions (prosurvival and proapoptotic). Kinases may
affect p53, proapoptotic BH3-only proteins, antiapoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, A1, Mcl-1,
Bcl-w), proapoptotic, multidomain Bcl-2 proteins (Bax and Bak) as well as mitochondrial functions.
The BH3-only protein Bid is cleaved by caspase-8 in response to death ligands, resulting in activated,
truncated Bid (tBid). The activation of Bcl-2 proteins results in the release of proapoptotic, mitochondrial
factors such as cytochrome c (CytC), second mitochondria-derived activator of caspase (Smac),
apoptosis-inducing factor (AIF), and endonuclease G (EndoG). In contrast, reactive oxygen species
(ROS) production may result from mitochondrial dysfunction but appears as largely independent of Bcl-2
proteins. Further abbreviations: Csp-3, -6, -7, -9, caspases; cIAPs, cellular inhibitor of apoptosis proteins;
Apaf-1, apoptotic protease activating factor; ATP, adenosine triphosphate. Arrowheads indicate
activation while blunt ends indicate inhibition; scissors (
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and Mcl-1 have been described [15,40,42].  
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only proteins can be activated in the course of various cellular stress situations either by induced 
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Puma [44]. Furthermore, several subsequent steps are regulated by cellular kinases, such as by 
phosphorylation of antiapoptotic Bcl-2 proteins, by phosphorylation of Bax, or by affecting 
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important role of intrinsic, proapoptotic pathways in melanoma, pro- and antiapoptotic Bcl-2 
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In many cells, extrinsic apoptosis pathways have to be enhanced through the mitochondrial
pathway, which is based on processing and activation of the proapoptotic Bcl-2 protein Bid through
caspase-8 [34,35]. In melanoma cells, direct caspase activation in response to death ligands (CD95L and
TRAIL) appears as less active. Thus, the mitochondrial activation loop via Bid appears of particular
importance, which is also shown by the critical role of Bcl-2 protein expression for death ligand
sensitivity [15,27,36].
Mitochondrial permeability is critically controlled by Bcl-2 proteins, which enclose antiapoptotic
(Bcl-2, Mcl-1, Bcl-xL, Bcl-w, and A1), proapoptotic multidomain (Bax and Bak), as well as a number
of proapoptotic BH3-only proteins (e.g., Bid, Bim, Bad, Puma, and Noxa) [37]. Bcl-2 proteins are
under tight self-control, based on their mutual heterodimerization (Figure 3). According to present
models, mitochondrial permeability is mediated by the proapoptotic multidomain proteins Bax and
Bak, which form mitochondrial pores or induce pore formation [38,39]. The antiapoptotic Bcl-2 proteins
may heterodimerize with Bax or Bak to keep them in check. Different antiapoptotic Bcl-2 proteins may
substitute each other [40,41], and in melanoma cells the particular roles of Bcl-2, Bcl-xL, and Mcl-1 have
been described [15,40,42].
The next control level is built up by the group of BH3-only proteins, which can heterodimerize with
the different antiapoptotic Bcl-2 proteins in a competitive way to thus release Bax and Bak. BH3-only
proteins can be activated in the course of various cellular stress situations either by induced expression,
or by translocation and/or protein modification, e.g., phosphorylation [37,43]. In this way, BH3-only
proteins function as sensitizers for apoptosis induction through inhibition of antiapoptotic Bcl-2 proteins.
In addition, some of them may also directly activate Bax, as reported for Bid, Bim, and Puma [44].
Furthermore, several subsequent steps are regulated by cellular kinases, such as by phosphorylation
of antiapoptotic Bcl-2 proteins, by phosphorylation of Bax, or by affecting mitochondrial functions
to release ROS [11,45,46] (Figure 3). Due to the important role of intrinsic apoptosis pathways in
melanoma cells, Bcl-2 proteins appear as critical targets for melanoma therapy [15,47], and particularly
efficient apoptosis induction was found for Bim and Puma [38,48,49].
5. Critical Role of Apoptosis Deficiency in Melanoma
In normal tissue, homeostasis is maintained by a well-balanced equilibrium of cell proliferation
and cell death [50]. Because of its critical meaning for the cell´s fate, apoptosis pathways are tightly
regulated. Induction of apoptosis also serves as an important safeguard mechanism to prevent
cancer by eliminating potentially harmful cells. A defective proapoptotic signaling thus represents a
critical hallmark of cancer [9]. Apoptosis deficiency firstly permits initial tumor growth, and then it
critically contributes to therapy resistance in advanced cancer. Apoptosis deficiency can be mediated
by activation of antiapoptotic signals as well as by inactivation of proapoptotic pathways. Due to the
important role of intrinsic, proapoptotic pathways in melanoma, pro- and antiapoptotic Bcl-2 proteins
come into particular focus [47,51].
The pronounced chemotherapy resistance of melanoma is highly suggestive for deficient apoptosis
programs [36]. Survival pathways are frequently activated, as seen by the high frequency of
mutations in N-RAS (Rat sarcoma oncogene; 10–25%) and in BRAF (40–60%) [52]. The pathways of
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR appear as particularly promising targets for melanoma.
Thus, selective BRAF inhibitors have been approved [53–55], and combinations of BRAF and MEK
inhibitors as well as combinations of BRAF and PI3K/AKT inhibitors are presently evaluated [56–58].
The role of these pathways for apoptosis sensitivity of melanoma cells has been shown [13,59].
Activation of death receptors appears as an attractive and additional therapeutic strategy for cancer.
Death ligands may induce apoptosis independently of p53, in contrast to most chemotherapeutic
drugs, and may thus overcome drug resistance due to lacking p53 signaling [60]. While the CD95/Fas
ligand and TNF-α appear as problematic for systemic treatment due to severe side effects, such as liver
toxicity and induced inflammation, TRAIL has been shown to induce apoptosis in several cancers,
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while normal cells are largely protected [61–63]. In fact, TRAIL showed only few side effects in clinical
trials. However, the clinical efficacy of TRAIL monotherapy was also limited [64–67].
6. Inducible Resistance Limits TRAIL-Induced Apoptosis in Melanoma Cells
TRAIL may induce apoptosis via its two agonistic receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2
(Figure 1). Although melanoma cells reveal constitutive expression of DR5, this does not guarantee
TRAIL sensitivity. Thus, about half of melanoma cell lines with sole DR5 expression showed intrinsic
TRAIL resistance. On the other hand, all melanoma cell lines, which express DR4 in addition to DR5,
were characterized by initial TRAIL sensitivity. Importantly, most melanoma tissues do express both
receptors suggesting that initial TRAIL sensitivity is also characteristic for clinical melanoma [16,28].
The causes of intrinsic TRAIL resistance are not entirely understood and may also differ. Thus,
reduced expression of agonistic receptors was reported for TRAIL-resistant cells of small cell lung
carcinoma [68], while TRAIL-resistant cutaneous T-cell lymphoma cells were characterized by
constitutive expression of c-FLIP as well as by loss of caspase-10 and Bid [69]. In other cancers,
such as in cervical cancer, TRAIL resistance was related to the expression of TRAIL decoy receptors [70].
In melanoma cells, intrinsic TRAIL resistance was correlated with the expression of caspase antagonists
such as elevated expression of XIAP, survivin, and c-FLIP [28,71].
Apart from the problem of possible intrinsic TRAIL resistance, initially sensitive cancer cells may
develop an inducible resistance upon TRAIL treatment, as reported for several cell types such as those
of breast, colon, liver, and ovarian cancer [72–74]. A comparable situation is seen in melanoma; namely,
both DR4+DR5+ and DR4−DR5+ melanoma cells may develop inducible TRAIL resistance upon TRAIL
treatment. Due to the high rate of DR4 expression in melanomas and initial TRAIL sensitivity of DR4+
melanoma cells, inducible TRAIL resistance appears as the major problem in melanoma. It correlates
with downregulation of the two agonistic TRAIL receptors, of initiator caspases-8 and -10, as well as
of some proapoptotic Bcl-2 proteins, as shown for Bax, Bid, and Bim [17,75]. While intrinsic TRAIL
resistance may be excluded in patients by a forehanded screening, the development of inducible
TRAIL resistance may critically limit the achievement of TRAIL-based therapy. Inducible resistance
may therefore explain the so far only limited efficacy of TRAIL or TRAIL receptor agonists in clinical
trials [64–66].
7. Multiple Strategies Sensitize Melanoma Cells for TRAIL-Induced Apoptosis
To overcome the problem of inducible TRAIL resistance, different combination strategies have been
tested in tumor models [76]. With regard to melanoma cells, several distinct strategies were identified
that could sensitize TRAIL-induced apoptosis. These included chemotherapeutics, irradiation,
endoplasmatic reticulum (ER) stress induction, natural compounds, HDAC (histone deacetylase)
inhibitors, metabolic inhibitors and signaling inhibitors, reviewed in [27], as well as inhibition of TAK1
(transforming growth factor β-activated kinase 1) [77] and interferon-β [78]. In addition, survival
pathway inhibitors, presently considered for the clinic, resulted in enhanced TRAIL-induced apoptosis
and were able to overcome induced TRAIL resistance, including inhibitors for BRAF and MEK [13,79],
PI3K/AKT [59], ABL [80], ATM [81], PKC [82], and IKK [83].
The puzzling multitude of several, largely unrelated strategies demanded the unravelling of
common principles. In melanoma cells, several lines of evidence indicated that enhanced TRAIL
sensitivity goes hand in hand with cell cycle inhibition, as induced by the different strategies. Thus,
TRAIL-induced apoptosis was also enhanced, and inducible resistance was overcome by culturing
melanoma cells at high cell confluence or changing to serum-free conditions, which both resulted in cell
cycle inhibition. The common regulation step of TRAIL sensitization in melanoma thus appears to be
in parallel with the regulation of the cell cycle [84]. A cascade of kinases is involved here, in particular
enclosing cyclin-dependent kinases (CDKs) [85].
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8. Decisive Function of the SMAC/XIAP Rheostat
Several experimental data showed that the extrinsic caspase cascade in response to TRAIL was
blocked in resistant melanoma cells at the level of caspase-3. Thus, the initial processing step of
procaspase-3 to a 20 kDa intermediate product was seen, but its final processing to a mature 17 kDa
product was prevented [13,19,83,86]. Although the initial cleavage is mediated by caspase-8, the final
processing depends on caspase-3 autocatalytic activity [87]. These findings strongly indicated the role
of cIAPs, which block effector caspase activity (Figure 3).
In melanoma cells, XIAP seems to play this particular role in TRAIL sensitization. Thus,
concomitant downregulation of XIAP was seen in combinations of TRAIL with ultraviolet B (UVB)
radiation, HDAC inhibitors, chemotherapeutics, metabolism, and kinase inhibitors. Downregulation
of XIAP further correlated with complete caspase-3 processing and enhanced apoptosis. Finally,
overexpression of XIAP protected melanoma cells from apoptosis induced by TRAIL and combinations,
whereas its siRNA-mediated knockdown could sensitize melanoma cells for TRAIL [19,27,83,88,89].
In apoptosis pathways, Smac serves as an antagonist of XIAP (Figure 3), suggesting that the
release of Smac is a critical step in TRAIL sensitization. The important role of the Smac/XIAP rheostat
was demonstrated in pancreatic and bladder cancer by using small molecule inhibitors for XIAP as well
as Smac mimetics, which both enhanced TRAIL sensitivity [90,91]. In melanoma cells, the critical role
of Smac was proven by knockdown strategies. Thus, Smac knockdown abolished apoptosis induced
by TRAIL and combinations [13,19,83]. These data suggest the central role of the Smac/XIAP rheostat
in melanoma for TRAIL sensitivity. A reinforced mitochondrial release of Smac, which is supported by
pathway inhibitors, can overcome inducible TRAIL resistance in melanoma.
9. Critical Contribution of Mitochondrial Pathways and Bcl-2 Proteins
The critical importance of intrinsic apoptosis pathways for melanoma was already shown
previously [15,36]. Thus, activation of mitochondrial pathways was a central issue for different
strategies used in TRAIL sensitization, as seen by the loss of mitochondrial membrane potential and
release of proapoptotic mitochondrial factors [13,27,83,84]. Importantly, apoptosis induction by the
different pathway inhibitors alone was mostly insufficient, but apoptosis was efficiently induced by a
combination with TRAIL. This suggests that the pathway inhibitors opened a gate towards sensitivity,
but TRAIL was needed to provide the final proapoptotic signal.
In cells with induced resistance, clear signs of TRAIL signaling were still seen, such as processing of
caspase-8 and of Bid [13,83]. Bid may antagonize Bcl-2 [43]; however, this was apparently not sufficient
for apoptosis induction in resistant melanoma cells. Nevertheless, Bid appeared as essential for
apoptosis induction by TRAIL in combination with pathway inhibitors, as shown by Bid knockdown.
The critical role of Bcl-2 proteins in the enhancement of TRAIL-induced apoptosis was further
demonstrated by Bax knockdown and Bcl-2 overexpression [19,59,83]. Thus, in melanoma cells with
induced resistance, the initial steps of the pathway were still active; this was, however, not sufficient
for apoptosis induction.
The release of Smac is tightly controlled by pro- and antiapoptotic Bcl-2 proteins (Figure 3).
The principle dependency of TRAIL combinations on Bcl-2 proteins was proven by Bcl-2 overexpression
and by Bax knockdown, which both diminished apoptosis induction [19,59,83,88,92]. Furthermore,
downregulation of antiapoptotic Bcl-2 proteins (Bcl-2, Mcl-1, and Bcl-xL) was reported in melanoma
cells upon treatment with different therapeutic strategies used for TRAIL sensitization, such as
chemotherapeutics and inhibitors for metabolism, HDACs, and kinases. On the other hand,
proapoptotic BH3-only proteins were frequently upregulated in the course of TRAIL sensitization [27].
Particularly important roles are attributed to Bim and Puma, as both may interact with all antiapoptotic
Bcl-2 family members [49]. Bim or Puma were also upregulated in the course of TRAIL sensitization
by HDAC, BRAF, and cell cycle inhibition [12,83,84,93]. The control of Bim by MAP kinases is based
on its phosphorylation through ERK, which triggers its proteasomal degradation [11,94]. In addition,
Puma expression may be upregulated in the course of MAPK inhibition through the transcription
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factor FoxO3a [95]. Of the quite large number of BH3-only proteins, usually only a few have been
investigated in these studies. They may, therefore, have an even higher impact on TRAIL sensitization
in melanoma than presently known.
The two multidomain, proapoptotic Bcl-2-related proteins Bax and Bak represent a bottleneck in
mitochondrial apoptosis pathways. They are antagonized due to heterodimerization by the different
antiapoptotic Bcl-2 proteins and may be activated by BH3-only proteins, either directly or indirectly
through the inhibition of antiapoptotic Bcl-2 proteins (Figure 3). Both Bax and Bak can mediate
apoptosis in melanoma cells [40,41], but for TRAIL-induced apoptosis and for TRAIL sensitization,
particularly Bax appeared to be responsible [96]. Thus, typical activation steps for Bax (mitochondrial
translocation and conformational changes) were observed in melanoma cells by the combination of
TRAIL with pathway inhibitors [13,19,59,79,80,83,93]. It is worth noting that Bax activation happened
early after treatment (<4 h) and was thus not a consequence of induced apoptosis. In agreement with
its critical role, siRNA-mediated Bax knockdown abrogated apoptosis induction in melanoma cells by
combinations of TRAIL and inhibitors [59,83].
Concerning the regulation of Bax, an inactivating phosphorylation at Ser-184 as well as an activating
phosphorylation at Thr-167 have been reported [97,98]. By using Bax phosphorylation-specific
antibodies and flow cytometry, we could prove that Bax activation by IKK, PI3K, and AKT inhibitors
correlated with suppressed Ser-184 phosphorylation as well as with enhanced Thr-167 phosphorylation.
Both changes appeared as immediate effects (within 1–2 h) and were independent of induced
apoptosis [59,83]. The inhibited phosphorylation at Ser-184 had been related to AKT activity [45,97],
whereas the enhanced phosphorylation at Thr-167 was related to JNK, p38, and ERK pathways [98,99].
With regard to the Thr-167 phosphorylation in the course of PI3K inhibition, we have seen a further
relation to the production of reactive oxygen species (ROS). Thus, antioxidants prevented Thr-167
phosphorylation and partially rescued melanoma cells from wortmannin/TRAIL-induced apoptosis [59].
The significance of ROS for apoptosis regulation in melanoma cells was reported [100–102], and ROS
was also involved in sensitization of melanoma cells for TRAIL by cell cycle inhibition [84]. Together,
these data suggest that an early Bax activation is the critical step in sensitization of melanoma cells for
TRAIL, which then allows release of Smac.
10. Conclusions
TNF-related apoptosis-inducing ligand (TRAIL) represents a promising antitumor strategy,
which may also apply for the treatment of cutaneous melanoma. A particular task is to overcome the
problem of inducible TRAIL resistance. Several strategies for enhancing TRAIL-induced apoptosis
and for overcoming inducible TRAIL resistance are presently evaluated. One important approach is
the development of novel TRAIL receptor agonists, as the first-generation TRAIL receptor agonists
did not show sufficient clinical efficacy. Thus, hvTRA (APG350) is a synthetic fusion protein which
consists of two covalently linked, trivalent single-chain TRAIL receptor-binding domains, resulting in
a hexavalent binding mode, which can strongly enhance the proapoptotic signal [103]. In melanoma,
hvTRA efficiently induced apoptosis and led to sustained growth reduction in cell lines and xenograft
models [104].
Several lines of evidence have underlined the critical role of the Smac/XIAP rheostat in induced
TRAIL resistance in melanoma cells. Smac mimetics are presently evaluated for cancer therapy [105].
Although melanoma cells are largely insensitive to these mimetic drugs when used as single agents,
combinations with TRAIL or TRAIL receptor agonists appear as promising [106]. Thus, the IAP
antagonists Birinapant and AT-406 could sensitize BRAFV600E colorectal tumor cells for TRAIL-induced
apoptosis [107].
As TRAIL-induced apoptosis in melanoma cells and Smac release are essentially controlled by Bcl-2
proteins, the targeting of antiapoptotic Bcl-2 proteins appears as an important strategy for enhancing
TRAIL sensitivity. BH3-only proteins function as sensitizers for apoptosis induction, and particular
roles for apoptosis regulation in melanoma have been attributed to Bim and Puma [38,48,49]. A number
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of BH3 mimetics have been established, e.g., ABT-737, ABT-263, A-1155463, and S63845, as well as
ABT-199 (Venetoclax), which has been approved for treatment of refractory chronic lymphocytic
leukemia [38,108,109]. Although BH3 mimetics were less effective in melanoma cells as a single therapy,
they revealed synergistic effects in combinations, e.g., with immunotoxins or the proteasome inhibitor
bortezomib [42,110]. Due to the in vitro data, one might also expect good combination effects for BH3
mimetics and TRAIL in melanoma cells, as has been previously shown in glioma cells [111].
A major issue of this review article is the consideration of combinations of pathway inhibitors
and TRAIL for melanoma therapy. An important advantage is that many kinase inhibitors are already
approved for the clinic. The mechanism of enhanced TRAIL-induced apoptosis by pathway inhibitors
is based on the understanding that despite induced resistance, TRAIL still results in caspase-8 and Bid
activation. Bid can antagonize Bcl-2, which is, however, not sufficient for activation of the mitochondrial
apoptosis pathway. This may depend on the activity of other antiapoptotic Bcl-2 proteins and/or on an
inactivated Bax, as regulated by kinases (Figure 4).
Upon TRAIL sensitization by pathway inhibitors, the regulation level of kinases is decisively
changed, resulting in cell cycle arrest as well as in Bax activation. The regulation of Bax may further
depend on BH3-only proteins. Now, the mitochondrial gate is open, Smac is released, and the inhibition
of apoptosis by XIAP is overcome. Then, caspase-3 can undergo the final activation step through
autoprocessing, and apoptosis is induced (Figure 4). With an improved understanding of the interplay
of the pathway inhibitors and TRAIL, new combination strategies may be designed, which may allow
the utilization of the proapoptotic potential of TRAIL for melanoma therapy.
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The interplay of extrinsic and intrinsic apoptosis pathways for TRAIL signaling in melanoma cells is
shown. Important steps are the activation of Bax and the release of Smac. Further explanations are
given in the text. Abbreviations: CM, cytoplasma membrane; DISC, death-inducing signaling complex.
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